Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.74 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | IL1B | P01584 | 1/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19556664 | 0.86 | CRBN (1.00) | CRBNIKZF2IKZF3DDB1BRD4 | |
| SCHEMBL27097754 | 0.86 | CRBN (1.00) | CRBNIKZF2IKZF3DDB1BRD4 | |
| SCHEMBL476917 | 0.86 | CRBN (1.00) | CRBNIKZF2IKZF3DDB1BRD4 | |
| SCHEMBL19556665 | 0.86 | CRBN (1.00) | CRBNIKZF2IKZF3DDB1BRD4 | |
| SCHEMBL23660924 | 0.84 | CRBN (0.59) | CRBNIKZF2IKZF3DDB1BRD4 | |
| SCHEMBL27322536 | 0.80 | CRBN (0.49) | CRBNIKZF2IKZF1 | |
| SCHEMBL20128661 | 0.79 | CRBN (0.64) | CRBNIKZF2IKZF3DDB1BRD4 | |
| SCHEMBL23561126 | 0.79 | CRBN (0.64) | CRBNIKZF2IKZF3DDB1BRD4 | |
| SCHEMBL23860862 | 0.79 | CRBN (0.55) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL18270886 | 0.79 | CRBN (0.85) | CRBNIKZF2IKZF3DDB1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101124215-A | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | CELGENE CORP (US) | 2008-02-13 | — | — | CN | claimed |
| CN-1984657-A | Compositions comprising immunomodulatory compounds and methods of use for the treatment and management of myeloproliferative diseases | CELGENE CORP (US) | 2007-06-20 | — | — | CN | claimed |
| CN-1968695-A | Compositions comprising immunomodulatory compounds for the treatment and control of myelodysplastic syndromes and using methods | CELGENE CORP (US) | 2007-05-23 | — | — | CN | claimed |
| CN-1956718-A | Compositions comprising immunomodulatory compounds for the treatment and management of skin diseases and disorders, and method of using the same | CELGENE CORP (US) | 2007-05-02 | — | — | CN | claimed |
| CN-1897945-A | Compositions comprising immunomodulatory compounds for the treatment, amelioration and management of pain and methods of use thereof | CELGENE CORP (US) | 2007-01-17 | — | — | CN | claimed |
| CN-1713917-A | Compositions containing immunomodulatory compounds for the treatment and management of myelodysplastic syndromes and methods of use | CELGENE CORP (US) | 2005-12-28 | — | — | CN | claimed |
| CN-102505006-A | Modulation of stem and progenitor cell differentiation, assays, and uses thereof | CELGENE CORP | 2012-06-20 | — | — | CN | disclosed |
| CN-1756836-B | Modulation, identification and use of stem and progenitor cell differentiation | CELGENE CORP. (US) | 2011-12-14 | — | — | CN | disclosed |
| CN-101966183-A | Methods and compositions for the treatment and management of hemoglobinopathy and anemia | CELGENE CORP | 2011-02-09 | — | — | CN | disclosed |
| CN-1984657-B | Compositions comprising immunomodulatory compounds and methods of use for the treatment and management of myeloproliferative diseases | CELGENE CORP | 2010-12-15 | — | — | CN | disclosed |
| CN-1913896-B | Methods and compositions for the treatment and management of hemoglobinopathies and anemia | CELGENE CORP | 2010-12-01 | — | — | CN | disclosed |
| CN-100579527-C | Compositions containing immunomodulatory compounds for the treatment and management of myelodysplastic syndromes and methods of use | CELGENE CORP | 2010-01-13 | — | — | CN | disclosed |
| CN-101564390-A | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes | CELGENE CORP (US) | 2009-10-28 | — | — | CN | disclosed |
| CN-1956718-A | Compositions comprising immunomodulatory compounds for the treatment and management of skin diseases and disorders, and method of using the same | CELGENE CORP (US) | 2007-05-02 | — | — | CN | disclosed |
| CN-1921758-A | Immunomodulatory compounds for the treatment of central nervous system disorders | CELGENE CORP (US) | 2007-02-28 | — | — | CN | disclosed |
| CN-1913896-A | Methods and compositions for the treatment and management of hemoglobinopathies and anemia | CELGENE CORP (US) | 2007-02-14 | — | — | CN | disclosed |
| CN-1897945-A | Compositions comprising immunomodulatory compounds for the treatment, amelioration and management of pain and methods of use thereof | CELGENE CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1756836-A | Modulation, identification and use of stem and progenitor cell differentiation | CELGENE CORP (US) | 2006-04-05 | — | — | CN | disclosed |
| CN-1713917-A | Compositions containing immunomodulatory compounds for the treatment and management of myelodysplastic syndromes and methods of use | CELGENE CORP (US) | 2005-12-28 | — | — | CN | disclosed |
| CN-1658848-A | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds | CELGENE CORP (US) | 2005-08-24 | — | — | CN | disclosed |